Autopsies of 15 COVID-19 cases showed SARS-CoV-2 in multiple organs (lungs, heart, liver, etc.) even in non-immunocompromised individuals.
The virus mutated differently in each organ, supporting theories of viral reservoirs and rapid evolution.
“The SARS-CoV-2 spike protein stays in the brain after a COVID-19 infection.”
“Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
Altogether, our results suggest that in some individuals, a standard 5-day course of nirmatrelvir-ritonavir starting around the time of symptom onset may not completely eliminate the virus. Thus, after treatment ends, the virus can rebound if an effective adaptive immune response has not fully developed. These findings on the role of target cell preservation and incomplete viral clearance also offer a possible explanation for viral rebounds following other antiviral treatments for SARS-CoV-2.”
SARS-CoV-2 peptide fragments can reassemble with dsRNA into proinflammatory complexes, amplifying immune responses.
These complexes trigger cytokine secretion in various cell types, mimicking severe COVID-19 inflammation.
“Stunning interview w former @CDCgov director, virologist Robert Redfield:
COVID vaccines ‘Do not prevent infection & didn’t impact kinetics of pandemic…They don’t work that well, they’re not durable. What does work better is antiviral drug development [EARLY TX!!!] & we haven’t invested heavily there... Annual flu vaccines only work 25-50% of the time. Vaccines…won’t protect us against bird flu.’”
“Evidence is now clear from scientists in the field that this virus persists and even quietly replicates in the colon for years The question we are beginning to answer: is this virus oncogenic meaning can it lead to cancer in years to come?”
“Here is the first randomized trial to show that an antiviral can prevent Long Covid.
In the PANORAMIC trial, people randomized to molnupiravir had less risk of Long Covid than people who received no antivirals
My comment in the link below. A short🧵”
Literally living WITH Covid.
The use of antivirals to reduce the risk of long COVID is grounded in the hypothesis that viral persistence and possible ongoing replication of SARS-CoV-2 are major mechanistic pathways responsible for long COVID
ANTIVIRAL THERAPIES FOR PERSISTENT COVID/LONG COVID 83% SUCCESS 70 of 84 cases with the aggravating factor of immunosuppression
The types of treatment were grouped into: Prolonged Antiviral therapy Combination Antivirals Mixed therapy: Antiviral +Antibody
Thread: Hey, folks. The Chinese government woke up years ago with the repurposing of Azvudine, producing nine billion pills that protected the thymus of their population and specifically targets HIV's Vif protein, preserving the CD4 population. The West chose to rot. End of story.
Among other findings of this study, reactivation of viral herpes (EBV/CMV/HSV2) and CONFIRMED PERSISTENT SARS-CoV-2 INFECTIONS
This study is really about the diagnostic tool, and confirmation of viral persistence was part of proving the tool works. This is a step in the direction of a SarsCov2 test similar to HIV test.
New study shows #SARSCoV2 in skull sawdust at autopsy in 22 deceased persons with confirmed #COVID19.
by PCR (2/22, 9.1%) and by culture (1/22, 4.5%) in skull sawdust, suggesting that live virus is present in tissues postmortem, including bone.